tradingkey.logo

Street View: Leqselvi's US launch to boost sales for India's Sun Pharma

ReutersJul 15, 2025 4:38 AM

- ** Sun Pharma SUN.NS, India's top drugmaker by revenue, launched its anti-baldness drug Leqselvi in the U.S., following the settlement of a patent dispute with Incyte Corp INCY.O

** Shares up 0.6%; pharma index .NIPHARM trading flat

POTENTIAL $1 BLN OPPORTUNITY

** Nuvama ("hold"; PT: 1,830 rupees) estimates $300-$400 mln annual sales from Leqselvi by FY30, with peak sales potential of $1 bln in future

** Sees Leqselvi becoming U.S. blockbuster drug for co

** Morgan Stanley ("overweight"; PT: 1,960 rupees) says Leqselvi's commercialisation in U.S. includes "aggressive" patient support programme, indicating Sun Pharma's intent to drive early adoption amid competition from Pfizer PFE.N, Eli Lilly LLY.N

** Elara Capital ("accumulate"; PT: 1,871 rupees) sees Leqselvi becoming Sun Pharma's second-largest product

** Says that with limited treatment options, innovative drugs like Leqselvi remain important

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI